Clinical Trials Logo

Filter by:
NCT ID: NCT06227689 Recruiting - HPV Vaccine Clinical Trials

Effectiveness of Vaccine Chatbot on HPV Vaccine Awareness and Vaccination in China

Start date: January 18, 2024
Phase: N/A
Study type: Interventional

This interventional study targets female students in junior middle school. It goal is to evaluate the effectiveness of a vaccine chatbot on HPV vaccine awareness and vaccination. The main questions it aims to answer are: 1. How will the novel digital tool, a vaccine chatbot, impact eligible parents' awareness and knowledge of HPV vaccines, their willingness to vaccinate their daughters, and vaccination status of female students. 2. How is the vaccine chatbots accepted by all stakeholders, and what are the facilitators of and barriers to implementing vaccine chatbot promotion campaign. The intervention group will go through the intervention measure while the control group will not: 1. The intervention group will be invited to use the HPV vaccine chatbot online through WeChat , the mostly widely used social media platform in mainland China, or any web browsers. They can ask any questions related to the HPV vaccine and get validated answers from the chatbot immediately. The intervention lasts two weeks, with invitations sent every four days to reinforce the intervention. 2. The control group will not use the chatbot during the intervention duration. Researchers will compare participants' HPV vaccine awareness, and vaccination intention and status after intervention between intervention group and control group to evaluate if the vaccine chatbot improves HPV vaccine awareness and vaccination.

NCT ID: NCT06227429 Recruiting - Clinical trials for Hereditary Tyrosinemia, Type I

A Non-interventional, Post-Marketing Study to Describe Outcome of Nitisinone Treatment in HT-1 Patients

Start date: December 14, 2023
Phase:
Study type: Observational

This is a prospective, non-interventional, non-comparative, multicenter study to collect data on HT-1 patients in China treated with Nitisinone in a routine clinical setting. No tests or examinations are mandated in the study.

NCT ID: NCT06227325 Not yet recruiting - Gastric Cancer Clinical Trials

Disitamab Vedotin Combined With Sintilimab and XELOX Perioperative Treatment for Resectable Gastric Caner With HER2 Overexpression

Start date: February 1, 2024
Phase: Phase 2
Study type: Interventional

The aim of this study is to observe the efficacy, safety, postoperative pathological response rate and survival benefit of RC48 combined withSintilimab and chemotherapy in perioperative therapy of locally advanced resectable gastric and gastroesophageal junction adenocarcinoma.

NCT ID: NCT06227286 Not yet recruiting - Clinical trials for Mitral Regurgitation

Enhanced External Counter Pulsation on Afterload Mismatch Rate in Post-TEER (PAMPER)

Start date: March 1, 2024
Phase: N/A
Study type: Interventional

The goal of this multicenter, randomized, double-blind controlled study is to learn about the individuals after transcatheter edge-to-edge mitral valve repair (TEER). The main questions it aims to answer are: (1) can enhanced external counterpulsation (EECP) reduce the prevalence of afterload mismatch after TEER? (2) can EECP prevent the major adverse cardiac events after TEER? Participants will be randomly assigned into EECP or Sham-EECP intervention after TEER. Researchers will compare the EECP and Sham-EECP to see if it helps reduce the prevalence of afterload mismatch after TEER.

NCT ID: NCT06227195 Completed - Osteoarthritis Clinical Trials

Mechanism of IL-10 Pathway-mediated Regulatory B Cell Dysfunction in Osteoarthritis

Start date: January 1, 2019
Phase:
Study type: Observational

Our previous work has shown that Treg function is impaired in OA patients, but the cause of Treg deficiency has not been investigated. Since Breg has been shown to promote Treg differentiation and tissue repair, it is highly likely that the absence of the immunomodulatory effect of Breg in OA patients leads to impaired Treg differentiation. Based on the above data, we hypothesized that Breg plays a protective role in the course of OA by regulating T cell composition and promoting Treg differentiation through the secretion of anti-inflammatory factor IL-10

NCT ID: NCT06227156 Recruiting - Clinical trials for Castration-resistant Prostate Cancer

Disitamab Vedotin in the Treatment With HER2- Expression, Subjects With Locally Advanced or Metastatic Castration-resistant Prostate Cancer

Start date: April 8, 2024
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the effectiveness of Disitamab Vedotin in the treatment of subjects with locally advanced or metastatic castration-resistant prostate cancer.

NCT ID: NCT06227117 Recruiting - Breast Cancer Clinical Trials

Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer

Start date: July 27, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the Safety and Efficacy of Neoadjuvant study of DV in combination Toripalimab i or sequence chemotherapy in HR-negative, HER2 low-expressing Breast Cancer

NCT ID: NCT06226922 Completed - Clinical trials for Nausea and Vomiting, Postoperative

Risk Factors for Postoperative Nausea and Vomiting in Surgical Patients Undergoing Patient-controlled Intravenous Analgesia.

Start date: July 1, 2023
Phase:
Study type: Observational

The purpose of this study is to identify the risk factors for postoperative nausea and vomiting (PONV) in surgical patients undergoing patient-controlled intravenous analgesia (PCIA).

NCT ID: NCT06226896 Recruiting - Alport Syndrome Clinical Trials

Effects of Dapagliflozin on Progression of Alport Syndrome

Start date: November 15, 2023
Phase:
Study type: Observational

Recently, a series of large clinical trials have confirmed the cardio-renal protective effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors. but few patients with hereditary nephritis were included in these studies. This study is to evaluate the effects of dapagliflozin on slowing kidney disease progression in patients with Alport syndrome.

NCT ID: NCT06226480 Recruiting - Clinical trials for Postoperative Delirium

Machine Learning Algorithm for Predicting Postoperative Delirium in Elderly Patients After Thoracic Surgery

POD
Start date: February 25, 2024
Phase:
Study type: Observational

Postoperative delirium (POD) is a common and severe complication in patients undergoing major surgery, especially in the elderly. POD has been proven to be associated with increased morbidity and mortality, institutionalization, and high healthcare costs. This retrospective cohort study aimed to use machine learning methods to develop clinically meaningful models to support clinical decision making.